Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Issue 6 (7th May 2019)

• Record Type: Journal Article
• Authors: Wharton, Sean; Liu, Aiden; Pakseresht, Arash; Nørtoft, Emil; Haase, Christiane L.; Mancini, Johanna; Power, G. Sarah; Vanderlelie, Sarah; Christensen, Rebecca A. G.
• Is Part Of: Obesity. Volume 27:Issue 6(2019)
• Page Start: 917
• Page End: 924
• Publication Date: 2019-05-07
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.22462
• Languages: English
• ISSNs: 1930-7381

Abstract

Abstract : Objective: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. Methods: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. Results: The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m 2, and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively. Conclusions: In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss.